Gluconeogenic enzyme fructose 1,6‐bisphosphatase 1 (FBP1) loss disrupts hepatic metabolism and promotes HCC development through the hepatic stellate cell senescent secretome, and treatment with dasatinib/quercetin can target the elimination of senescent HSCs driven by hepatic FBP1 loss, dampening tumour progression.149. Here, FBP1 is linked to hepatocellular carcinoma.